
Research News
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Dr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Presentation Summaries from the 10th Annual Retinal Therapy Innovation Summit
In its tenth year, the Innovation Summit featured 28 presentations from industry professionals worldwide and more than 400 attendees.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Despite missing the primary endpoint, the treatment improved vision for some patients.
-
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
Retinitis Pigmentosa Research Advances
Recent developments in research on retinitis pigmentosa.
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease
-
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis